NQO1

A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms

Sarah K. Beaver, Noel Mesa-Torres, Angel L. Pey, David J. Timson

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

NAD(P)H quinone oxidoreductase 1 (NQO1) is a multi-functional protein that catalyses the reduction of quinones (and other molecules), thus playing roles in xenobiotic detoxification and redox balance, and also has roles in stabilising apoptosis regulators such as p53. The structure and enzymology of NQO1 is well-characterised, showing a substituted enzyme mechanism in which NAD(P)H binds first and reduces an FAD cofactor in the active site, assisted by a charge relay system involving Tyr-155 and His-161. Protein dynamics play important role in physio-pathological aspects of this protein. NQO1 is a good target to treat cancer due to its overexpression in cancer cells. A polymorphic form of NQO1 (p.P187S) is associated with increased cancer risk and certain neurological disorders (such as multiple sclerosis and Alzheimer´s disease), possibly due to its roles in the antioxidant defence. p.P187S has greatly reduced FAD affinity and stability, due to destabilization of the flavin binding site and the C-terminal domain, which leading to reduced activity and enhanced degradation. Suppressor mutations partially restore the activity of p.P187S by local stabilization of these regions, and showing long-range allosteric communication within the protein. Consequently, the correction of NQO1 misfolding by pharmacological chaperones is a viable strategy, which may be useful to treat cancer and some neurological conditions, targeting structural spots linked to specific disease-mechanisms. Thus, NQO1 emerges as a good model to investigate loss of function mechanisms in genetic diseases as well as to improve strategies to discriminate between neutral and pathogenic variants in genome-wide sequencing studies.
Original languageEnglish
Pages (from-to)663-676
Number of pages14
JournalBBA - Proteins and Proteomics
Volume1867
Issue number7-8
DOIs
Publication statusPublished - 12 May 2019

Fingerprint

Flavin-Adenine Dinucleotide
NAD
Neoplasms
Proteins
Genetic Suppression
Quinones
Inborn Genetic Diseases
Xenobiotics
Nervous System Diseases
Multiple Sclerosis
Oxidation-Reduction
Catalytic Domain
Alzheimer Disease
Oxidoreductases
Antioxidants
Binding Sites
Communication
Genome
Pharmacology
Apoptosis

Keywords

  • Quinone oxidoreductase
  • Multiple sclerosis
  • Alzheimer’s disease
  • Protein misfolding
  • Antioxidant enzyme
  • Pharmacological chaperone
  • Alzheimer's disease

Cite this

@article{8d94a2e728c34f32beff26f79c7a9392,
title = "NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms",
abstract = "NAD(P)H quinone oxidoreductase 1 (NQO1) is a multi-functional protein that catalyses the reduction of quinones (and other molecules), thus playing roles in xenobiotic detoxification and redox balance, and also has roles in stabilising apoptosis regulators such as p53. The structure and enzymology of NQO1 is well-characterised, showing a substituted enzyme mechanism in which NAD(P)H binds first and reduces an FAD cofactor in the active site, assisted by a charge relay system involving Tyr-155 and His-161. Protein dynamics play important role in physio-pathological aspects of this protein. NQO1 is a good target to treat cancer due to its overexpression in cancer cells. A polymorphic form of NQO1 (p.P187S) is associated with increased cancer risk and certain neurological disorders (such as multiple sclerosis and Alzheimer´s disease), possibly due to its roles in the antioxidant defence. p.P187S has greatly reduced FAD affinity and stability, due to destabilization of the flavin binding site and the C-terminal domain, which leading to reduced activity and enhanced degradation. Suppressor mutations partially restore the activity of p.P187S by local stabilization of these regions, and showing long-range allosteric communication within the protein. Consequently, the correction of NQO1 misfolding by pharmacological chaperones is a viable strategy, which may be useful to treat cancer and some neurological conditions, targeting structural spots linked to specific disease-mechanisms. Thus, NQO1 emerges as a good model to investigate loss of function mechanisms in genetic diseases as well as to improve strategies to discriminate between neutral and pathogenic variants in genome-wide sequencing studies.",
keywords = "Quinone oxidoreductase, Multiple sclerosis, Alzheimer’s disease, Protein misfolding, Antioxidant enzyme, Pharmacological chaperone, Alzheimer's disease",
author = "Beaver, {Sarah K.} and Noel Mesa-Torres and Pey, {Angel L.} and Timson, {David J.}",
year = "2019",
month = "5",
day = "12",
doi = "10.1016/j.bbapap.2019.05.002",
language = "English",
volume = "1867",
pages = "663--676",
journal = "BBA - Proteins and Proteomics",
issn = "1570-9639",
number = "7-8",

}

NQO1 : A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms. / Beaver, Sarah K.; Mesa-Torres, Noel; Pey, Angel L.; Timson, David J.

In: BBA - Proteins and Proteomics, Vol. 1867, No. 7-8, 12.05.2019, p. 663-676.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - NQO1

T2 - A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms

AU - Beaver, Sarah K.

AU - Mesa-Torres, Noel

AU - Pey, Angel L.

AU - Timson, David J.

PY - 2019/5/12

Y1 - 2019/5/12

N2 - NAD(P)H quinone oxidoreductase 1 (NQO1) is a multi-functional protein that catalyses the reduction of quinones (and other molecules), thus playing roles in xenobiotic detoxification and redox balance, and also has roles in stabilising apoptosis regulators such as p53. The structure and enzymology of NQO1 is well-characterised, showing a substituted enzyme mechanism in which NAD(P)H binds first and reduces an FAD cofactor in the active site, assisted by a charge relay system involving Tyr-155 and His-161. Protein dynamics play important role in physio-pathological aspects of this protein. NQO1 is a good target to treat cancer due to its overexpression in cancer cells. A polymorphic form of NQO1 (p.P187S) is associated with increased cancer risk and certain neurological disorders (such as multiple sclerosis and Alzheimer´s disease), possibly due to its roles in the antioxidant defence. p.P187S has greatly reduced FAD affinity and stability, due to destabilization of the flavin binding site and the C-terminal domain, which leading to reduced activity and enhanced degradation. Suppressor mutations partially restore the activity of p.P187S by local stabilization of these regions, and showing long-range allosteric communication within the protein. Consequently, the correction of NQO1 misfolding by pharmacological chaperones is a viable strategy, which may be useful to treat cancer and some neurological conditions, targeting structural spots linked to specific disease-mechanisms. Thus, NQO1 emerges as a good model to investigate loss of function mechanisms in genetic diseases as well as to improve strategies to discriminate between neutral and pathogenic variants in genome-wide sequencing studies.

AB - NAD(P)H quinone oxidoreductase 1 (NQO1) is a multi-functional protein that catalyses the reduction of quinones (and other molecules), thus playing roles in xenobiotic detoxification and redox balance, and also has roles in stabilising apoptosis regulators such as p53. The structure and enzymology of NQO1 is well-characterised, showing a substituted enzyme mechanism in which NAD(P)H binds first and reduces an FAD cofactor in the active site, assisted by a charge relay system involving Tyr-155 and His-161. Protein dynamics play important role in physio-pathological aspects of this protein. NQO1 is a good target to treat cancer due to its overexpression in cancer cells. A polymorphic form of NQO1 (p.P187S) is associated with increased cancer risk and certain neurological disorders (such as multiple sclerosis and Alzheimer´s disease), possibly due to its roles in the antioxidant defence. p.P187S has greatly reduced FAD affinity and stability, due to destabilization of the flavin binding site and the C-terminal domain, which leading to reduced activity and enhanced degradation. Suppressor mutations partially restore the activity of p.P187S by local stabilization of these regions, and showing long-range allosteric communication within the protein. Consequently, the correction of NQO1 misfolding by pharmacological chaperones is a viable strategy, which may be useful to treat cancer and some neurological conditions, targeting structural spots linked to specific disease-mechanisms. Thus, NQO1 emerges as a good model to investigate loss of function mechanisms in genetic diseases as well as to improve strategies to discriminate between neutral and pathogenic variants in genome-wide sequencing studies.

KW - Quinone oxidoreductase

KW - Multiple sclerosis

KW - Alzheimer’s disease

KW - Protein misfolding

KW - Antioxidant enzyme

KW - Pharmacological chaperone

KW - Alzheimer's disease

UR - http://www.scopus.com/inward/record.url?scp=85065799843&partnerID=8YFLogxK

U2 - 10.1016/j.bbapap.2019.05.002

DO - 10.1016/j.bbapap.2019.05.002

M3 - Review article

VL - 1867

SP - 663

EP - 676

JO - BBA - Proteins and Proteomics

JF - BBA - Proteins and Proteomics

SN - 1570-9639

IS - 7-8

ER -